Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Non-Current Assets: 2009-2024

Historic Other Non-Current Assets for Cytokinetics (CYTK) over the last 14 years, with Dec 2024 value amounting to $7.7 million.

  • Cytokinetics' Other Non-Current Assets rose 117.61% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 117.61%. This contributed to the annual value of $7.7 million for FY2024, which is 3.64% down from last year.
  • Cytokinetics' Other Non-Current Assets amounted to $7.7 million in FY2024, which was down 3.64% from $8.0 million recorded in FY2023.
  • Cytokinetics' Other Non-Current Assets' 5-year high stood at $9.7 million during FY2022, with a 5-year trough of $6.4 million in FY2020.
  • Over the past 3 years, Cytokinetics' median Other Non-Current Assets value was $8.0 million (recorded in 2023), while the average stood at $8.5 million.
  • In the last 5 years, Cytokinetics' Other Non-Current Assets surged by 34.82% in 2022 and then declined by 17.49% in 2023.
  • Cytokinetics' Other Non-Current Assets (Yearly) stood at $6.4 million in 2020, then climbed by 13.05% to $7.2 million in 2021, then spiked by 34.82% to $9.7 million in 2022, then decreased by 17.49% to $8.0 million in 2023, then declined by 3.64% to $7.7 million in 2024.